The world's first bivalent mRNA vaccine candidate against respiratory syncytial virus, or RSV, kicked off Phase I clinical ...

Novavax has received the green light from the US Food and Drug Administration (FDA) to resume clinical trials for its ...

The number of COVID cases increased last week to 146. Cases had been falling in April and May and were as low as 31 at the ...

Novavax said the Food and Drug Administration allowed it to continue testing a combination COVID-19-flu and standalone flu vaccine that had been put on hold.

It would be unhealthy to let Robert F. Kennedy Jr. take charge of U.S. physical well-being. President-elect Donald Trump said on the campaign trail that he wants the anti-vaccine activist to “run wild ...

FDA Approvals and Expansions In May, the FDA approved the mRNA-1345 RSV vaccine (mResvia) from Moderna for people ages 60 and ...

Vermont has the second lowest state fatality rate in the US (141.1 per 100K; Hawaii 111.7/100K). Mississippi (457.4/100K) and ...

Northeastern University professors of pharmacy say the updated COVID-19 vaccines available for fall and winter of 2024 are a ...

Moderna, Inc. (NASDAQ:MRNA) is a pharmaceutical and biotechnology company specializing in RNA therapeutics, particularly mRNA vaccines. The company gained widespread recognition for its COVID-19 ...

Since their introduction last year, researchers have been monitoring the real-world impact of the new respiratory syncytial ...

Since their introduction last year, researchers have been monitoring the real-world impact of the new respiratory syncytial virus (RSV) vaccines.

On Monday, Merck & Co Inc (NYSE:MRK) and Moderna, Inc. (NASDAQ:MRNA) announced the initiation of INTerpath-009, a pivotal Phase 3 trial of V940 (mRNA-4157). V940 is an investigational ...